Khater, N., Abd ELrahman, H., Mohammed, R., Elashery, M. (2022). Evaluation of Serum Visfatin in Children and Adolescent with Type1 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 86(1), 324-328. doi: 10.21608/ejhm.2022.212025
Nahed Mahmoud Khater; Hadeel Mohammed Abd ELrahman; Randa Hussieny Mohammed; Mahmoud Ali Elashery. "Evaluation of Serum Visfatin in Children and Adolescent with Type1 Diabetes Mellitus". The Egyptian Journal of Hospital Medicine, 86, 1, 2022, 324-328. doi: 10.21608/ejhm.2022.212025
Khater, N., Abd ELrahman, H., Mohammed, R., Elashery, M. (2022). 'Evaluation of Serum Visfatin in Children and Adolescent with Type1 Diabetes Mellitus', The Egyptian Journal of Hospital Medicine, 86(1), pp. 324-328. doi: 10.21608/ejhm.2022.212025
Khater, N., Abd ELrahman, H., Mohammed, R., Elashery, M. Evaluation of Serum Visfatin in Children and Adolescent with Type1 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 2022; 86(1): 324-328. doi: 10.21608/ejhm.2022.212025
Evaluation of Serum Visfatin in Children and Adolescent with Type1 Diabetes Mellitus
Background: Type 1 diabetes mellitus (T1DM) is a chronic illness characterized by the body’s inability to produce insulin due to the autoimmune destruction of the beta cells in the pancreas. Visfatin is a ubiquitous intracellular enzyme, known as nicotine amide phosphoribosyl transferase (NAMPT) and pre-B-cell colony-enhancing factor (PBEF-1). Objective: The aim of this study was to evaluate serum visfatin level in children and adolescent with type 1 diabetes mellitus (T1DM). Patients and methods: The present study was a case-control study observation that was conducted in Pediatric Endocrinology Unit, Pediatric Ward, Zagazig University Hospitals. The study included 46 children; 23 with T1DM and 23 healthy age- and sex- matched children. Results: In this study, we found that serum visfatin level in diabetic group is statistically highly significant lower than healthy group. The mean serum level of visfatin in healthy group was 19.53 ± 10.5 ng/ml, while in T1DM patients was 2.85 ± 2.09 ng/ml. The best cutoff of serum visfatin level in excluding T1DM was ≥ 3.6 ng/ml with area under curve 0.968 with sensitivity 91.3%, specificity 82.6%, positive predictive value 84%, negative predictive value 90.5%, positive likelihood ratio 5.25, negative likelihood ratio 0.11 and accuracy 87% (p < 0.001). The result showed that serum visfatin could be helpful in prediction of T1DM among children and adolescents with an accuracy 87%. Conclusion: Serum visfatin level is lower in T1DM patients compared to healthy control. Visfatin play a role in early prediction and understanding the mechanism of its action in T1DM could lead to new therapeutic targets.